| Name | Title | Contact Details |
|---|
Genomic Health, Inc. (NASDAQ: GHDX) is the world`s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient`s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.
Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and nucleic acid-based therapeutics. Arcturus Therapeutics is presently recruiting outstanding candidates with experience in the field of RNA technologies and nanoparticle sciences. Only exceptional applicants need apply. Compensation and equity position is commensurate.
Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets. Organovo is changing the shape of medical research and practice.